Nektar Therapeutics Narrows Q1 Net Loss to $44.9M on Lower G&A Costs
Summary
Nektar Therapeutics reported a Q1 net loss of $44.90 million, or $1.82 per share, which narrowed from the prior year, with revenue slightly increasing to $10.86 million. The improved bottom line was primarily due to a decrease in general and administrative expenses, particularly legal costs, despite an increase in R&D spending for its rezpegaldesleukin development. This quarterly update provides new financial performance data for the company and is not redundant with the recent proxy filing. While the company remains unprofitable, the narrowing loss indicates some progress in cost management. Investors will be watching for the planned initiation of the Phase 3 rezpegaldesleukin trial in atopic dermatitis by July 2026 and the anticipated End-of-Phase 2 FDA meeting for its alopecia areata program in Q2 2026 as key upcoming catalysts.
At the time of this announcement, NKTR was trading at $82.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $7.99 to $109.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.